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Available online 12 April 2014AbstractPurpose: The clinical significance of VEGF-A expression in gastric cancer (GC) has been reported with contradicting results. We analyzed
the expression and clinical significance of VEGF-A in a wide Italian cohort of GC specimens.
Methods: VEGF-A expression was tested by immunohistochemistry in 507 patients with GC of all clinical stages. The impact of VEGF-A
on overall survival (OS) was evaluated in conjunction with clinical and pathological parameters.
Results: In the Italian cohort we studied VEGF-A was not an independent prognostic factor neither at the univariate nor at multivariate
analysis.
Conclusions: Although frequently expressed, in our study VEGF-Awas not able to discriminate between groups of patients with different risk.
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GC is the fourth most common cancer and the second
leading cause of cancer-related death worldwide.1 The
vast majority of GC are adenocarcinomas; they are diag-
nosed after they have invaded the muscularis propria and
are therefore classified as Advanced Gastric Cancers
(AGC). The detection of a GC which is still confined to
the mucosa and submucosa (Early Gastric Cancer, EGC)
leads to a better prognosis.2 It has been demonstrated that
GC incidence and mortality show geographic variability
and Europe has an intermediate incidence rate, between
high incidence countries (such as Japan) and low incidence
countries (African countries).3 Despite earlier diagnosis,
radical surgery and the development of novel adjuvant ther-
apies, including target therapies, have improved prognosis
for GC, the 5-years survival rate, across all the TNM stages,
is only about 28%, based on data provided by the American
Cancer Society. Moreover, Japanese survival rates are
higher than those observed in Western countries and within
Europe, consistent differences can be observed.4 Standard
chemotherapy, both in resectable and advanced disease,
has however limited efficacy. Hence, the identification of
novel molecular markers, as well as new cancerogenetic
mechanisms and targets for therapeutic interventions, are
urgently needed to improve prognosis.
A relevant aspect of tumor growth is represented by
intratumoral angiogenesis. It has been hypothesized that
cancer cells begin to promote angiogenesis early in tumori-
genesis. This early “angiogenic switch”5 is characterized by
oncogene-driven tumor expression of pro-angiogenic pro-
teins.6 Among them, the Vascular Endothelial Growth
Factor-A (VEGF-A) is one of the most relevant angiogenic
factors,7 whose expression is regulated by both oxygen ten-
sion8 and polypeptide growth factors, cytokines, as well as
oncogenic mutations of relevant intracellular signaling com-
ponents (reviewed in Ref. 9). VEGF-A and its receptors
have been identified to critically influence tumor-related
angiogenesis, in several cancer types, including GC.10
VEGF-A impact on prognosis has been demonstrated by
meta-analysis in different cancers such as hepatocellular11
and pancreatic cancer.12 Despite numerous studies, however,
the prognostic significance of VEGF expression in GC is
still under debate13e21 and an extensive meta-analysis has
been recently published22 showing that ethnicity is a predic-
tive factor of the effect of VEGF-A on prognosis.
Very few papers evaluating VEGF-A clinical significance
in big cohorts of non-Asian individuals have been published
so far. The majority of the studies analyzed Asian patients
whose pathological characteristics are quite different from
those of Western countries’ subjects. Indeed, from a compar-
ison between a Japanese and a British cohort23 it emerged a
prevalence of Lauren’s intestinal type in European patients,
and of diffuse type in Japanese subjects. Moreover, the Jap-
anese cohort showed high percentages of TNM stage I and IIwith respect to stages III and IV, while in the British cohort
the distribution was more homogeneous.
The present paper was aimed at better defining the
expression profile and prognostic role of VEGF-A in a
wide Italian cohort of GC samples, encompassing all path-
ological stages.
Materials and methodsPatients and tissue specimensTissue samples (n¼ 190) were prospectively obtained af-
ter informed written consent from patients who underwent
surgery with curative or palliative intent for primary gastric
cancers at the Department of Surgery and TranslationalMed-
icine, University of Florence and the General Surgery and
Surgical Oncology, Azienda Ospedaliero-Universitaria,
Careggi, Florence, Italy. Patients affected by viral hepatitis
or who had undergone pre-operative radiotherapy or chemo-
therapywere excluded from the study. Samples were taken in
the operating room and a sample of paired normal gastricmu-
cosa was collected from the operative specimens at least
10 cm from the tumor, and from the same region of the stom-
ach containing the tumor, when applicable.
Moreover, a multicenter cohort of GC archival samples
(n ¼ 389) mainly assembled as Tissue Micro Arrays was
collected by Department of Pathology and Diagnostics
(University of Verona), Department of Pathological Anat-
omy (AOUS, Siena), Department of General Surgery and
Oncology (University of Siena), Pathology Division, Borgo
Trento Hospital (Verona), General Surgery and Division of
Pathology, Morgagni-Pierantoni Hospital (Forlı).
Diagnosis and histological grading were assessed in all
cases using standard criteria by experienced pathologists
(LM, AT, CV, and LS). The study population was represented
by 508 patients with complete follow up information.Immunohistochemistry (IHC)Due to the broad expression of VEGF-A in stromal cells
of the gastric submucosa24 that might raise false positive re-
sults with standard molecular techniques, VEGF-A expres-
sion was retrospectively tested by IHC, and performed as
previously reported25 using anti-VEGF-A antibody (Poly-
clonal antibody anti VEGF-A (A-20), Santa Cruz Biotech-
nology; Santa Cruz CA, USA, 1: 100 dilution). As a
preliminary step, we validated the antibody performing
Western Blot assays and immunocytochemistry (see below)
and optimized the IHC procedure25 in different primary tis-
sues (high grade astrocytomas, renal tissue and normal
colorectal tissue), that served as positive internal controls
for VEGF-A staining. The staining background due to the
expression of VEGF-A in stromal and inflammatory cells
was considered as non-specific staining. Nevertheless,
while evaluating the immunohistochemistry results only
Table 1
Characteristics of patients excluded and included into the statistical ana-
lyses and distributions of clinical and pathological variables after multiple
imputation of missing values.
Variable Patients
excluded from
the analyses
(N ¼ 71)
Patients
included
into the
analyses
(N ¼ 508)
Study
cohort
after
multiple
imputation
(N ¼ 508)
No. (%) No. (%) %
Age, years
Median (range) 71 (31e86) 67.5 (30e90) 68 (30e90)
<70 31 (43.7) 290 (57.1) 57.3
70 39 (54.9) 216 (42.5) 42.7
Missing value 1 (1.4) 2 (0.4) e
Gender
Male 44 (62.0) 324 (63.8) 63.8
Female 27 (38.0) 184 (36.2) 36.2
Site of primary tumor
Antrum,
cardias
49 (69.0) 231 (45.5) 45.7
Body 14 (19.7) 131 (25.8) 25.9
Fundus 4 (5.6) 113 (22.2) 22.3
Gastric stump,
linitis plastica
2 (2.8) 31 (6.1) 6.1
Missing value 2 (2.8) 2 (0.4) e
TNM stage
I 28 (39.4) 69 (13.6) 13.6
II 10 (14.1) 89 (17.5) 17.5
III 19 (26.8) 190 (37.4) 37.5
IV 12 (16.9) 159 (31.3) 31.3
Missing value 2 (2.8) 1 (0.2) e
Pathological grading
G1 7 (9.9) 24 (4.7) 4.9
G2 27 (38.0) 154 (30.3) 31.5
G3 27 (38.0) 292 (57.5) 61.5
G4 0 (e) 9 (1.8) 2.1
Missing value 10 (14.1) 29 (5.7) e
Lauren type
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primary antibody) were included in each IHC experiment.
After dewaxing and dehydrating the sections, endogenous
peroxidases were blocked with a 1% H2O2 solution in
PBS. Subsequently, antigen retrieval was performed with
Proteinase K (5 mg/ml) Because of the intracellular locali-
zation of the antigens, tissue permeabilization was required,
therefore treatment with blocking solution and permeabili-
zation were carried out (Ultra V Block containing 0.1%
Triton X100, LabVision; Fremont CA, USA). Antibodies
were incubated overnight at 4 C. Immunostaining was per-
formed with a commercially available kit (PicTure Max kit,
Invitrogen; Carlsbad CA, USA) according to manufac-
turer’s instructions. Stained sections were analyzed at a to-
tal magnification of 40 field by field, from top left to
bottom right. A significant VEGF-A labeling was detected
in GC samples where the protein was mainly expressed in
the cytoplasm of cancerous epithelial cells, with a low
expression in the tumor stroma. To evaluate the VEGF-A
status of the samples, only epithelial-derived tumor cells
were taken into account, while the signal detected in stro-
mal or inflammatory cells was not considered. VEGF-A
was scored as the number of positive tumor cells over total
tumor cells, first setting the threshold value, using different
cut offs. Percentage scores were then categorized using the
0% cutoff (0% staining vs any staining), the 10% cutoff
(<10% tumor cell staining vs 10%), the 25% (<25% tu-
mor cell staining vs 25%) and the 50% (<50% tumor cell
staining vs 50%). Since the vast majority of the samples
belonged to the highest score categories, no substantial dif-
ference emerged in the three cut off values groups (10%,
25%, 50%). In particular, the percentages of low score sam-
ples were 12.3%, 14.2% and 16.1% (with <10%, <25%
and <50% cut-offs, respectively) while high score samples
were 87.7%, 85.8% and 83.9% (with >10%, >25% and
>50% cut offs, respectively). We argued that no significant
biological differences characterized the different scoring
groups. Hence, assignment of a positive score was per-
formed when the sample showed more than 10% positive
cells according to Galizia et al., 200426 and as previously
reported by other groups and by us.17,25 Results were eval-
uated by two independent investigators (EL and MRR). A
third joint observation with conclusive agreement as well
as the independent review of the slides by a third observer
(SB) was performed. When needed, an additional review by
experienced pathologists of each participating center was
performed. Interobserver agreement was evaluated accord-
ing to the simple Cohen’s k of concordance and its 95%
confidence interval.Intestinal 41 (57.7) 317 (62.4) 63.8
Diffuse 20 (28.2) 128 (25.2) 25.5
Mixed 5 (7.0) 53 (10.4) 10.7
Western Blot (WB)Missing value 5 (7.0) 10 (2.0) e
VEGF-A status
Negative 8 (11.3) 42 (8.3) 12.3
Positive 36 (50.7) 410 (80.7) 87.7
Missing value 27 (38.0) 56 (11.0) eDiluted serum samples were heated in reducing
Laemmli buffer (6.25 mM Tris-HCl pH 6.8, 1% glycerol,
2% SDS, 2% b-mercaptoethanol and 0.0012% bromophe-
nol blue) at 95 C for 5 min, separated by 10% SDS-PAGE and transferred to a PVDF membrane (Amersham).
After transfer, the membrane was blocked for 2 h at room
temperature with PBS þ Tween-20 0.1% (T-PBS), contain-
ing 5% BSA (T-PBS-BSA) and incubated overnight at 4 C
with anti-VEGF-A antibody (A-20, Santa Cruz Biotech-
nology), diluted 1:500 in T-PBS-BSA. The membrane
was then washed 3 times with T-PBS and incubated with
anti-rabbit peroxidase-conjugated secondary antibody
(Sigma) diluted 1:10,000 in T-PBS-BSA for 45 min at
room temperature. After 3 washes with T-PBS, the mem-
brane was revealed by a chemiluminescent reaction with
ECL (Amersham).
Figure 1. Anti-VEGF-A antibody specificity testing. A) WB experiments were performed on serum samples displaying high levels of VEGF-A (previously
determined by ELISA assay, mean value: 1399.14  251.88 pg/ml vs 661.81  121.44 pg/ml in healthy donor serum samples). A band corresponding to
about 24 kDa is evident (see arrow) showing the ability of the antibody to selectively bind VEGF-A monomer in reduced serum samples. B) ICC on
HCT116 cells secreting high levels of VEGF-A (7.3  2.5 ng/106 cells vs 2.2  0.17 in HEK293 cells29). A positive reaction is evident in the cytoplasm
of tumor cells, while is not detectable in the Control sample (with no primary antibody, panel on the left).
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Association between VEGF-A expression and clinical and pathological
variables.
Variable VEGF-A
positivity rate
OR (95% CI) P value
Age, years
<70 88.1% 1 (ref.) 0.564
70 87.2% 0.90 (0.44e1.85)
Gender
Male 88.2% 1 (ref.) 0.699
Female 86.9% 0.88 (0.43e1.81)ICC was performed on HCT116 cell line. Cells were
cultured in RPMI 1640 (Euroclone) supplemented with
10% Fetal Calf Serum (Euroclone) and 2 mM L-Glutamine.
Cells were grown on glass coverslips, washed twice in PBS
and fixed in 90% ethanol for 10 min at room temperature
with gentle agitation. Coverslips were then air-dried and
stored at room temperature. For ICC experiments, cover-
slips were treated with 0.1% H2O2 for 15 min at room tem-
perature, to ensure endogenous peroxidases blocking and
then incubated with Ultra Vision Protein Block solution
(Fisher Scientific) with 0.1% Triton X-100 for 20 min at
room temperature. Cells were then incubated with anti-
VEGF-A antibody (A-20, Santa Cruz Biotechnology)
diluted 1:100 in PBS-Ultra Vision Protein Block (10:1, v/
v) for 2 h at room temperature. Immunostaining was carried
out with PicTure Max kit and DAB (Invitrogen). For nega-
tive control samples, no primary antibody was added to the
PBS-Ultra Vision Protein Block solution. Coverslips were
then counterstained with Mayer Hematoxylin and mounted
on glass slides.Site of primary tumor
Antrum, cardias 88.0% 1 (ref.) 0.809
Body 89.0% 1.09 (0.49e2.43)Statistical analysisFundus 86.6% 0.88 (0.42e1.87)
Gastric stump,
linitis plastica
83.9% 0.70 (0.23e2.14)
TNM stage
I 82.5% 1 (ref.) 0.397
II 93.3% 2.67 (0.54e13.2)
III 88.2% 1.44 (0.34e6.14)
IV 86.4% 1.23 (0.27e5.68)
Pathological grading
G1, G2 91.3% 1 (ref.) 0.106
G3, G4 85.7% 0.55 (0.25e1.21)
Lauren type
Intestinal 90.6% 1 (ref.) 0.212
Diffuse 85.2% 0.58 (0.25e1.31)
Mixed 76.7% 0.33 (0.10e1.09)
Abbreviations: ref., reference group.The distributions of all studied patients were reported
with respect to their demographic, clinical, and biologic
characteristics and were summarized as frequencies and
percentage. Continuous variables were reported as median
and range of variation. To avoid the exclusion of cases
with missing data, the multiple imputation method was
used (10 imputations). Logistic regression and regression
methods were used for imputation of categorical and
continuous variables, respectively. Missing-at-random as-
sumptions were made. The following demographic, clinical
and biological variables were investigated: age at the inter-
vention, gender, site of primary, TNM stage, pathological
grading, Lauren type and VEGF-A status. Both in theassociation and survival analyses, age was categorized in
two groups (<70 years vs 70 years). As a measure of
the strength of the association between the VEGF-A
expression and each other characteristics, the odds ratio
(OR) value and its 95% confidence interval (CI) was esti-
mated with a univariate logistic regression model,
combining the results of the analyses of imputations. The
statistical significance of odds ratios was evaluated accord-
ing to the likelihood ratio test. All the variables were inves-
tigated for their impact on overall survival (OS). OS was
defined as the time between intervention and death,
Table 3
Univariate and multivariate evaluation of prognostic role for overall survival of clinical and pathological variables.
Variable Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Age, years
<70 1 (ref.) <0.001 1 (ref.) <0.001
70 1.63 (1.34e1.99) 2.29 (1.86e2.82)
Gender
Male 1 (ref.) 0.012 1 (ref.) 0.006
Female 0.77 (0.62e0.95) 0.74 (0.59e0.92)
Site of primary tumor
Antrum, cardias 1 (ref.) <0.001 1 (ref.) 0.023
Body 1.14 (0.89e1.47) 1.05 (0.81e1.34)
Fundus 1.37 (1.06e1.76) 1.20 (0.92e1.57)
Gastric stump, linitis plastica 2.52 (1.67e3.80) 1.98 (1.30e3.04)
TNM stage
I 1 (ref.) <0.001 1 (ref.) <0.001
II 2.17 (1.40e3.38) 2.36 (1.50e3.71)
III 4.05 (2.70e6.08) 4.50 (2.95e6.86)
IV 7.09 (4.68e10.7) 8.40 (5.39e13.1)
Pathological grading
G1, G2 1 (ref.) 0.207 1 (ref.) 0.045
G3, G4 1.14 (0.93e1.41) 0.76 (0.58e0.99)
Lauren type
Intestinal 1 (ref.) <0.001 1 (ref.) 0.017
Diffuse 1.55 (1.23e1.94) 1.36 (1.02e1.81)
Mixed 1.79 (1.30e2.45) 1.64 (1.14e2.35)
VEGF-A status
Negative 1 (ref.) 0.510 1 (ref.) 0.801
Positive 1.00 (0.59e1.68) 0.99 (0.70e1.40)
Abbreviations: ref., reference group.
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the last follow-up visit was censored. Median follow-up
time was estimated according to the KaplaneMeier inverse
method.27 Univariate and multivariate hazard ratios (HRs)
estimates, and appropriate 95% CIs, were calculated by
means of the Cox proportional hazard model, combining
the results of the analyses of imputations. The statistical
significance of HRs was evaluated according to the likeli-
hood ratio test. The multivariate Cox regression model
was fitted including in the model all the investigated param-
eters. The presence of interaction on OS between the
VEGF-A status and other characteristics was verified with
the interaction test. A two-sided P 0.05 was considered
significant in all analyses. No adjustment for multiple com-
parisons was made. Statistical analyses were performed by
LB using SAS version 9.2 (SAS Institute, Cary, NC).
ResultsCharacteristics of study cohortPatients were enrolled from different Italian centers
(Florence, Verona, Siena and Forlı). As shown in Table 1
the group of 71 patients excluded from analysis did not
significantly differ from the study population. Patient sam-
ples encompassed all TNM stages, with higher percentages
in stages III and IV. As it can be observed from Table 1, a
slight prevalence of males and G3 pathological gradecharacterized the cohort under study. Moreover, 63.8% of
the samples were classified as Lauren’s intestinal type, ac-
cording to the most frequent histotype in Italy.28
To confirm the specificity of anti-VEGF-A antibody,
preliminary experiments were performed. In particular,
Western Blot assay was performed on human serum sam-
ples with high VEGF-A levels (previously determined by
Human VEGF Quantikine ELISA kit). As shown in
Fig. 1A, WB results indicate that anti-VEGF-A antibody
specifically binds VEGF-A monomer in reduced serum
samples, in which a band of about 24 kDa is evident, ac-
cording to the product’s datasheet.
To further confirm the antibody specificity, ICC experi-
ments were carried out on HCT116 cell line, already char-
acterized for VEGF-A secretion.29 In Fig. 1B,
representative pictures of ICC experiments are reported,
showing VEGF-A expression in the cytoplasm of
neoplastic cells (right panel), while no immunostaining
can be observed in the negative control sample (left panel).
The expression of VEGF-A in primary GC was studied
only by IHC, due to the broad expression of VEGF-A in
stromal cells of the gastric submucosa.24 Normal gastric
mucosa did not express the protein (Fig. 2, panels A
and B), while a low expression was observed in the stroma
(more evident in panel B), as expected. When analyzing
tumor samples a significant VEGF-A labeling was de-
tected in GC samples of Lauren’s intestinal type (Fig. 2,
panels C and D) where the protein was mainly expressed
Figure 2. Immunohistochemical staining for VEGF-A in GC specimens. IHC experiments and assessment of score were performed as described in Materials
and methods. A) IHC of a representative specimen of normal gastric mucosa. The lining epithelium does not express the protein in contrast to the stroma. B)
Higher magnification of the same sample as in A). C) IHC of a Lauren’s intestinal type adenocarcinoma sample strongly positive for VEGF-A expression.
VEGF-A staining was intense and diffuse in the cytoplasm of tumor cells, with a weaker positivity in the stroma. D) Higher power microphotograph of the
sample reported in C. E) IHC of a diffuse type adenocarcinoma, showing no VEGF-A expression. F) Higher magnification picture of the sample in E). Images
were acquired with Aperio Image Scope v.11.0.2.725. Magnification: A, C, E: 6; B, D, F: 20.
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nuclei were negative, as expected. A lower expression
of the protein was observed in the tumor stroma
(Fig. 2D). Samples of the diffuse type turned out to be
negative (Fig. 2, panels E and F). A positive score for
VEGF-A was assigned when the sample showed more
than 10% positive cells.26On the whole, 87.7% of the samples expressed VEGF-A
with a high immunoreactivity score. No associations be-
tween clinicalepathological parameters and VEGF-A
expression emerged (Table 2).
The samples were evaluated by two independent investi-
gators and the k value related to the interobserver measure
of agreement was 0.92 (95% CI: 0.85e0.99).
Figure 3. Interaction analyses on OS between VEGF-A and other clinical and pathological parameters. Values of HR<1 indicate a protective role of VEGF-A.
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391 deaths were observed.
At the univariate analyses, age 70 years, male sex, site
(gastric stump and linitis plastica), advanced stages and
diffuse/mixed Lauren were associated with a worse prog-
nosis (Table 3). On the contrary, VEGF-A did not show
any impact on overall survival (OS) (HR ¼ 1.00, 95%
CI: 0.59e1.68; P ¼ 0.510). From the comparison of
early-onset GC (45 years) with late-onset GC (>45 years)
no statistically significant results emerged, due to the quite
low percentage of patients belonging to the early-onset
group (only 5%).
The multivariate analysis confirmed the results obtained
at the univariate analysis (Table 3).
Finally, one statistically significant interaction on OS
was observed between pathological grading and VEGF
expression (P ¼ 0.001) although not clinically relevant,
with an HR ¼ 1.07 in G1eG2 samples and a HR ¼ 0.95
in G3eG4 samples (Fig. 3).
Discussion
In the present paper we evaluated VEGF-A expression
and clinical significance in a huge cohort of non-Asian in-
dividuals suffering from GC. In particular, VEGF-A
expression was analyzed in a large series of GC patients
all belonging to Italian ethnicity, using methodologies and
antibodies employed in different Research and Medical
Centers.17,25 Study population was characterized by a slight
prevalence of males, G3 pathological grading and TNM
stages III and IV. As expected,28 the intestinal Lauren’shistological type prevailed. In our series, VEGF-A expres-
sion was not associated with clinico-pathological character-
istics and had no impact on overall survival. A statistically
significant interaction on OS was observed between patho-
logical grading and VEGF expression, although not clini-
cally relevant. It should be also noted that in our series
VEGF-A is expressed by the majority of samples (87.7%)
and this imbalance makes it quite difficult to draw precise
correlations.
To our knowledge a very few papers evaluating the prog-
nostic value of VEGF-A in big cohorts of non-Asian indi-
viduals have been published so far. In fact, the majority of
the studies analyzed Asian patients, whose pathological
characteristics are quite different from those of Western
countries’ subjects. In this case, data concerning VEGF-A
prognostic impact mainly address it as a negative fac-
tor.13,14,16,19,21 Only a paper, reporting data obtained in a
big cohort of patients, found no association between
VEGF-A expression and prognosis in GC evaluated by
IHC using paraffin-embedded samples,18 in agreement
with our findings. Moreover, a meta-analysis whose results
have been published in 2012,22 showed that VEGF-A
expression is associated with poor prognosis in Asian popu-
lation, while this correlation is lacking in non-Asian cohorts.
Similarly to the present, the study conducted by Lieto
et al.17 investigated the prognostic impact of VEGF-A
expression in patients of Italian origin, although reaching a
different conclusion. This discrepancy could be traced back
to the fact that Lieto et al. analyzed a smaller number (88
vs 508) of patients, with different clinico-pathological char-
acteristics, such as a higher percentage of diffuse type cases.
From this scenario, and our data support this hypothesis,
it emerges that VEGF-A expression has a negative
1298 E. Lastraioli et al. / EJSO 40 (2014) 1291e1298prognostic impact only in Asian GC patients,16,17,30e33
with low or null impact in Western country populations.
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